2-(3-Methylsulfanyl-1-phenylpyrazol-4-yl)-4-phenyl-1,3-thiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-Methylsulfanyl-1-phenylpyrazol-4-yl)-4-phenyl-1,3-thiazole
• 化学式: C₁₉H₁₅N₃S₂
• 分子量: 349.5
• InChiKey: PPULGEZXKVDKSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  84.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• METHODS AND COMPOSITIONS FOR THE INHIBITION OF FRUCTOKINASE
  申请人：The Regents of the University of Colorado, A Body Corporate

  公开号：EP2600897A2

  公开（公告）日：2013-06-12
• Methods and Compositions for the Treatment of RAS Associated Disorders
  申请人：Ratner Nancy

  公开号：US20120302581A1

  公开（公告）日：2012-11-29

  The instant disclosure relates to compositions that may be useful as therapeutic agents for the treatment of disorders associated or caused by Ras deregulation or dysregulation, for example, disorders associated with alterations in the NF1 gene such as neurofibromatosis type I, fungal infections such as those caused by Candida albicans , and proliferative disorders such as glioblastoma.
• Methods for Fructanase and Fructokinase Inhibition
  申请人：The Regents of the University of Colorado, A Body

  公开号：US20130195886A1

  公开（公告）日：2013-08-01

  Provided are methods and compositions method for inhibiting fructokinase activity within the gastrointestinal tract cell of a subject. The compositions and methods treat or prevent conditions associated with increased permeability and oxidative stress in the gastrointestinal tract of a subject.
• Methods and Compositions for the Inhibition of Fructokinase
  申请人：Johnson Richard J.

  公开号：US20130224218A1

  公开（公告）日：2013-08-29

  The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.
• METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE
  申请人：REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

  公开号：US20210275494A1

  公开（公告）日：2021-09-09

  The invention relates to the use of one or more fructokinase (ketohexokinase) (KHK) inhibitors to both prevent and treat a wide variety of diseases including, but not limited to, alcohol craving, alcohol addiction, alcohol induced liver disease including fatty liver and cirrhosis.